Drug intelligence / Profile preview

epiitalis

Development stage
Unknown
Lead developer
Interpath Global
Administration
Oral
01

Overview

Epiitalis is a proprietary, globally patented plant seed oil extract derived from *Biota orientalis*, developed by Interpath, and formulated as a dietary supplement for joint health in both humans and animals. It is characterized by unique fatty acids and is designed to reduce inflammation, enhance cartilage health, and support normal joint function. Epiitalis has been studied in multiple species—including humans, dogs, horses, and cats—and has demonstrated significant efficacy in reducing pain, improving joint function, and improving quality of life, particularly in osteoarthritis. Clinical studies show approximately 50% pain reduction in human knee osteoarthritis patients versus placebo, with similar improvements in function and quality of life. The precise molecular mechanism is under continued investigation, but evidence supports an anti-inflammatory effect and possible disease-modifying activity in joint pathology.

Brand names
EPIITALISEpiitalis Forte
Other names
Biota orientalis seed oil extract

Beyond the preview

Go deeper on epiitalis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epiitalis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call